Patent Expiry Unleashes 50+ Generic Semaglutide Brands in India's Weight-Loss Market

On Saturday, a patent expired in a quiet pharmaceutical office in Copenhagen, and the reverberations are about to reshape how millions of Indians manage their weight and diabetes. Novo Nordisk's semaglutide—the drug behind the brand names Ozempic and Wegovy—has been the exclusive property of one company for years. Now it belongs to no one, and over forty Indian pharmaceutical manufacturers are racing to fill the gap with their own versions.

The numbers tell the story of a market about to transform. Right now, semaglutide costs between ₹8,800 and ₹16,400 per month in India, depending on the brand and dosage. The generics will arrive at ₹3,000 to ₹5,000—less than half the price. That difference is not academic. It is the difference between a treatment someone can afford and one they abandon after a few months because the cost becomes unsustainable. Neeraj Tulara, a diabetologist and founder of Bookurdoc Speciality Clinics, has watched patients quit their therapy for exactly this reason. "Some people are not willing to continue for more than six months," he said. "They lose some weight and are dropping out because of the cost. Many of them will find the generics easier on the pocket."

India has 100 million people with diabetes and 250 million classified as obese. Yet only about 5 percent of diabetics and 4 percent of obese individuals currently use GLP-1 drugs like semaglutide. The untapped pool is vast. Industry analysts expect the market to grow from its current 4-5 percent penetration to 15-20 percent within the next 12 to 18 months. The anti-obesity drug market itself, valued at ₹1,500 crore today, could balloon to ₹4,000-5,000 crore within two years and reach ₹8,000 crore by 2030.

The companies preparing to launch include some of India's largest pharmaceutical names: Dr Reddy's, Sun Pharma, Eris, Zydus, Mankind, Alkem, MSN Laboratories, Intas Pharma, and Micro Labs. More than fifty distinct brands are in the pipeline. But here is where the story becomes complicated. These are companies accustomed to making tablets and capsules—small molecules that can sit on a shelf. Semaglutide is a biologic, a protein-based drug that must be kept cold from factory to patient. It requires refrigeration at every step. It comes in a device—a pen or injector—that must work reliably. It demands a supply chain most Indian drugmakers have never built before.

Rajiv Kovil, a diabetologist based in Mumbai, put it plainly: "When the patent goes off tomorrow, it's more about the back-end capability—from cold chain maintenance to supply robustness." The companies with the infrastructure to handle this—the ones with reliable refrigeration networks, quality manufacturing for biologics, and established relationships with doctors—will survive. The rest will not. Industry experts predict that within a year, only five to eight brands will dominate the market. The rest will fade.

There is another dimension to watch. Right now, only 1,200 to 1,500 doctors in India prescribe semaglutide regularly. That number is expected to jump to about 15,000 within a year as the drug becomes more affordable and accessible beyond the major cities. This expansion into smaller towns and secondary markets depends entirely on whether the generic manufacturers can deliver reliable cold chains and quality devices to places that have never had them before. It also depends on whether the drugs actually work. Tulara believes they will. "If generics continue to deliver even 80-85 percent of a similar effect as compared to the innovator molecule, generics will flourish," he said.

But doctors are also sounding an alarm. With cheaper versions flooding the market, the risk of misuse grows. Semaglutide is not a weight-loss miracle for everyone—it carries side effects, and it should be prescribed carefully by qualified physicians. "Misuse has to be controlled," Tulara warned. "Otherwise, with the rampant use of this, we will see a lot of side effects and problems. This has to be dispensed only on prescription and ideally written by a certain class of doctors." The regulatory framework that governs how these drugs reach patients will matter as much as the manufacturing capacity that produces them.

What happens next will depend on execution. The patent has expired. The opportunity is real. But turning that opportunity into actual access for millions of Indians—getting the cold chain right, getting the device right, getting the doctor network right—is a different challenge entirely. The next 12 to 18 months will determine which companies can manage it and which cannot.